Paper Details

  1. Home
  2. Paper Details

A Pre-Clinical Safety Evaluation of SBP (HBsAg-Binding Protein) Adjuvant for Hepatitis B Vaccine.

Author: KhanInam Ullah, LiuBaoxiu, LiuRui, SuCaixia, WangJingbo, XieJun, ZhuNaishuo

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigates the potential of SBP, a hepatitis B surface antigen binding protein, as a vaccine adjuvant. SBP was introduced into hepatitis B vaccine and demonstrated the ability to enhance HBsAg-specific immune response, potentially increasing the protection provided by the vaccine. Non-clinical safety evaluations showed no significant adverse effects, warranting further research into SBP as a safe and effective adjuvant.
Paper Details　
Original Abstract of the Article :
Although adjuvants are a common component of many vaccines, there are few adjuvants licensed for use in humans due to concerns about their toxic effects. There is a need to develop new and safe adjuvants, because some existing vaccines have low immunogenicity among certain patient groups. In this st...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5245819/

データ提供：米国国立医学図書館（NLM）

A Safe and Effective Adjuvant for Hepatitis B Vaccine: Exploring the Potential of SBP

This research explores the potential of a novel adjuvant, SBP, for enhancing the effectiveness of the hepatitis B vaccine. The researchers conducted a pre-clinical safety evaluation to assess the safety and immunogenicity of SBP when combined with the hepatitis B vaccine.

SBP: A Promising Adjuvant for Hepatitis B Vaccination

The study's findings suggest that SBP enhances the immune response to the hepatitis B vaccine, potentially increasing the level of protection against infection. The pre-clinical safety data indicates that SBP appears to be a safe and effective adjuvant, warranting further investigation in human trials to confirm its potential for improving hepatitis B vaccination outcomes.

Navigating the Desert of Vaccine Development

The development of new and safe adjuvants is crucial for enhancing the effectiveness of vaccines and providing greater protection against infectious diseases. This research contributes to this critical area, highlighting the potential of SBP as a promising adjuvant for hepatitis B vaccination. The findings encourage further research to assess the safety and efficacy of SBP in human populations, potentially leading to improved vaccination strategies for preventing hepatitis B infection.

Dr.Camel's Conclusion

The researchers have set out on a quest in the desert of vaccine development, searching for a safe and effective adjuvant to enhance the hepatitis B vaccine. Their discovery of SBP is like finding a precious oasis in the desert, offering hope for improved protection against this serious disease.
Date :
  1. Date Completed 2017-08-14
  2. Date Revised 2019-01-09
Further Info :

Pubmed ID

28103328

DOI: Digital Object Identifier

PMC5245819

Related Literature

Article Analysis
・Side Effects of hepatitis b vaccine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.